IRVING, Texas--(BUSINESS WIRE)--Vizient, Inc. announced today that Steven Lucio, PharmD, BCPS, senior principal, pharmacy solutions for Vizient, will share insights on biosimilars in the panel discussion, “Building the Sustainable Future of Biosimilars,” at the Festival of Biologics being held March 20-22 in San Diego.
Lucio, who has extensive expertise in biosimilars, educates healthcare organizations on the benefits of biosimilars and helps them develop strategies to include them in patient care. Last year he led a team that conducted a survey of hospital leaders and pharmacy professionals from across the country that found biosimilars are gaining inclusion in hospital formularies, something long seen as a necessity for greater adoption.
“Vizient continues to advocate for biosimilar adoption to create more competition in the market,” Lucio said. “Biosimilars are as effective as their originator biologic counterparts and represent an opportunity that, when fully optimized, can lower costs without compromising the quality of patient care.”
The panel discussion “Building the Sustainable Future of Biosimilars,” will take place on March 21 at 4:40 p.m. PDT.
About Vizient, Inc.
Vizient, Inc., the nation’s largest health care performance improvement company, serves more than 60% of the nation’s acute care providers, which includes 97% of the nation’s academic medical centers, and more than 25% of the non-acute market. Vizient provides expertise, analytics and advisory services, as well as a contract portfolio that represents more than $130 billion in annual purchasing volume. Vizient’s solutions and services improve the delivery of high-value care by aligning cost, quality and market performance. Headquartered in Irving, Texas, Vizient has offices throughout the United States. Learn more at www.vizientinc.com.
